NKSquared Lead USD 2.7 Mn Funding in Health-Tech Startup Biopeak
Biopeak will use the fresh funds to expand operations, open a new clinic, enhance diagnostics, advance AI tools, support research, and develop clinical programs.
You're reading Entrepreneur India, an international franchise of Entrepreneur Media.
Bengaluru-based health-tech startup Biopeak has secured USD 2.7 million in a follow-on funding round led by NKSquared, the investment vehicle of Zerodha co-founder Nikhil Kamath.
This marks Kamath’s second investment in the company, following a USD 1.43 million contribution in August 2024.
The startup plans to use the fresh capital to expand operations, including opening a new clinic, enhancing its diagnostics, advancing proprietary artificial intelligence (AI) tools, supporting research initiatives, and developing clinical programs.
Co-founded in 2025 by Rishi Pardal and Shiva Subramanian, Biopeak provides AI-driven molecular diagnostics, imaging, and expert-led programs aimed at optimising healthspan. Its approach, described as a “family health office” model, offers personalised plans for longevity, integrating technologies such as organic acid profiling, microbiome mapping, whole-exome functional genomics, salivary cortisol rhythms, and imaging methods including MRI, CT, DXA, and ECHO.
Biopeak’s in-house clinics deliver specialised care based on actionable insights covering nutrition, sleep, and stress. The startup focuses on high achievers, executives, and women, offering programs that combine advanced diagnostics, wearable data, specialist teams, and AI-driven recommendations tailored to Indian biology and disease patterns.
Over the past year, the company has expanded its client base and clinical offerings, responding to growing demand for structured longevity services. Following the launch of its first clinic in Bengaluru last year, Biopeak plans to open a second clinic in the coming month.
Bengaluru-based health-tech startup Biopeak has secured USD 2.7 million in a follow-on funding round led by NKSquared, the investment vehicle of Zerodha co-founder Nikhil Kamath.
This marks Kamath’s second investment in the company, following a USD 1.43 million contribution in August 2024.
The startup plans to use the fresh capital to expand operations, including opening a new clinic, enhancing its diagnostics, advancing proprietary artificial intelligence (AI) tools, supporting research initiatives, and developing clinical programs.
Co-founded in 2025 by Rishi Pardal and Shiva Subramanian, Biopeak provides AI-driven molecular diagnostics, imaging, and expert-led programs aimed at optimising healthspan. Its approach, described as a “family health office” model, offers personalised plans for longevity, integrating technologies such as organic acid profiling, microbiome mapping, whole-exome functional genomics, salivary cortisol rhythms, and imaging methods including MRI, CT, DXA, and ECHO.
Biopeak’s in-house clinics deliver specialised care based on actionable insights covering nutrition, sleep, and stress. The startup focuses on high achievers, executives, and women, offering programs that combine advanced diagnostics, wearable data, specialist teams, and AI-driven recommendations tailored to Indian biology and disease patterns.
Over the past year, the company has expanded its client base and clinical offerings, responding to growing demand for structured longevity services. Following the launch of its first clinic in Bengaluru last year, Biopeak plans to open a second clinic in the coming month.
